The United Kingdom and the United States have concluded a key bilateral deal that will guarantee zero tariffs on British drug shipments being sold in the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase spending on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that import taxes on these crucial products will be held at zero for a duration of 36 months.
This development comes after previous threats to dramatically increase duties on branded pharmaceutical products, with figures discussed as high as double the cost.
"This deal with the United Kingdom reinforces the international landscape for new treatments and establishes much-needed balance to transatlantic drug exports," an announcement noted.
Trade Importance
Drugs represent one of the Britain's most significant exports to the US, which is by far the largest destination for large British pharmaceutical firms.
Statistics reveal that in the 12 months prior to the third quarter, the UK shipped medicines worth £11.1bn to the US. This amount made up a significant portion of all goods exports in that period.
"This deal safeguards work, stimulates investment and paves the way for the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary commented.
Specific UK Commitments
The agreement involves several specific pledges from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to raise overall public funding on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be capped at fifteen percent. Previously, refunds topped twenty percent.
Industry Background
The deal takes place against a ongoing dispute between the drug companies and the UK government over spending levels and approval rates.
The disagreement were intensified by claims that American patients were charged several times more for the same drugs than consumers in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been paused or cancelled, while substantial investments have been pledged toward American operations.
One official acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the last ten years.
